In randomized trials with subgroup analyses, the primary treatment or intervention of interest is randomized, but the secondary factors defining subgroups are not. This article clarifies when confounding is an issue in subgroup analyses. If investigators are interested simply in targeting subpopulations for intervention, control for confounding is not needed. If investigators are interested in intervening on the secondary factors that define the subgroups to increase the treatment effect or in attributing the subgroup differences to the secondary factors themselves, then confounding is relevant and must be controlled for. The authors demonstrate this point by using examples from published randomized trials.
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www.annals.org For author affiliations, see end of text. P revious literature on subgroup analyses (1-6) focuses on data analysis and reporting rather than on the interpretation of effect heterogeneity (see below) itself when this heterogeneity is clinically and statistically significant. This literature discusses the importance of specifying subgroup analyses a priori, adjusting for multiple testing, and using proper statistical procedures for subgroup analyses. Other authors have noted the possibility of confounding in subgroup analyses but have not discussed when such confounding is relevant (4, 7) .
In this article, we clarify the settings in which confounding for secondary factors that define subgroups is important in the interpretation of subgroup analyses. We demonstrate that a distinction should be drawn between whether the effect of an intervention simply varies across strata of a secondary factor (referred to as "effect heterogeneity") or whether an intervention on the secondary factor would change the effect of the primary intervention (referred to as "causal interaction"). If effect heterogeneity is of interest, confounding for the secondary factors is not relevant; however, if causal interaction is of interest, confounding for the secondary factor must be controlled for.
CONFOUNDING IN SUBGROUP ANALYSES
Consider a subgroup analysis of a randomized trial that indicates that treatment is more effective in women than men. If the men in the study were substantially older than the women and if treatment were more effective in younger participants than older participants, then age rather than sex might be responsible for the differences in treatment effects between men and women. This possibility raises the question of when confounding is relevant in subgroup analyses.
On the one hand, treatment is randomized, and the treatment groups should be comparable even when they are divided into subgroups on the basis of baseline characteristics. On the other hand, the subgroups themselves (for example, men and women) may not be comparable with each other in terms of other baseline characteristics (for example, age).
Because treatment is randomized, comparing treatment with placebo in men and women would give a valid estimate of the treatment effects in these 2 subgroups, assuming adherence to study protocol and no differential loss to follow-up. The difference between these 2 estimates would give a valid measure of effect heterogeneity comparing men with women in the sample. However, we cannot necessarily attribute the difference in treatment effects to sex itself.
As Figure 1 shows, treatment effects may differ in men and women simply because these groups differ in age. Conceived of another way, at least in large samples, the effect of treatment within subgroups is not confounded because treatment is randomized; however, the effect of the secondary factor that defines the subgroups might be confounded because the secondary factor is not randomized.
If we are interested simply in assessing the treatment effect within subgroups, confounding does not need to be controlled for. However, if we are interested in attributing the differences in treatment effect to the secondary factor itself, then confounding of the secondary factor must be controlled for. If we controlled for age in the subgroup analysis and still found a difference in treatment effects between men and women, we would have evidence that the effect heterogeneity was not caused by age. However, we could not definitively conclude that the effect heterogeneity was attributable to sex unless we could control for all relevant differences (a sufficient set of confounders) between the men and women in the study.
Example 1
The distinction concerning when confounding is important becomes especially apparent if we consider possible interventions on the secondary factor. Consider a randomized trial on the effects of tiotropium on FEV 1 in patients with chronic obstructive pulmonary disease (8) . In subgroup analyses, the investigators found a statistically significant decrease in mean postbronchodilator FEV 1 when they compared tiotropium therapy with placebo only in the subgroup of patients who were not receiving either inhaled corticosteroids or long-acting ␤-agonists at baseline. This subgroup comprised 1554 of the 2554 patients included in the main analysis.
This subgroup analysis was a post hoc assessment, but suppose that these findings were accurate and replicable. If the investigators were interested simply in targeting groups in whom treatment was most effective, the subgroup analysis would validly indicate that, in comparable samples, treatment with tiotropium is more effective in persons not receiving inhaled corticosteroids or long-acting ␤-agonists at baseline than in persons receiving these agents.
However, suppose that we considered discontinuing corticosteroid or ␤-agonist therapy in patients receiving these agents. The subgroup analysis does not give definitive evidence that discontinuing these therapies would increase the effectiveness of tiotropium therapy. Persons not receiving corticosteroids or ␤-agonists may be healthier at baseline, and tiotropium may be more effective in these healthier persons.
We would not know whether we could attribute the effect heterogeneity across the corticosteroid or ␤-agonist treatment subgroups to corticosteroid or ␤-agonist therapy itself or to some other factor confounded with it. To answer this question, we would have to control for a set of factors that sufficiently control for confounding for the relationship between corticosteroid or ␤-agonist therapy and FEV 1 .
If we are interested simply in targeting subgroups to maximize the treatment effect, confounding for the secondary factor defining the subgroups is not necessary. However, if we are interested in intervening on the secondary factor to increase the treatment effect or if we want to attribute the effect heterogeneity to the secondary factor, then we need to account for confounding of the secondary factor. The secondary factor has not been randomized.
We could control for factors confounding the effect of the secondary factor by multivariate adjustment or by stratifying the analysis on the confounders for the secondary factor. However, to validly estimate how intervening on the secondary factor would change the effect of the primary intervention, all such relevant confounding factors would have to be controlled for in the analysis. Stratifying randomization on the secondary factor does not suffice to control for confounding of the secondary factor; it simply increases the probability that comparable numbers of participants receiving treatment and control participants would be included in each stratum of the secondary factor. Because the secondary factor is not randomized, it would The estimates of treatment effect in male and female participants are valid, but these differences in treatment effect might be caused by age rather than sex.
Key Summary Points
In subgroup analyses in randomized trials, the primary treatment is randomized, but the secondary factors defining subgroups generally are not; the potential need to control for confounding variables for the secondary factors depends on how the investigators want to interpret the results of the subgroup analyses.
If investigators are interested in whether the treatment effect varies across subgroups (effect heterogeneity) in order to target specific subgroups to maximize the treatment effect, then confounding for the secondary factor defining the subgroups is not necessary.
If investigators are interested in intervening on the secondary factor to increase the treatment effect or want to attribute the effect heterogeneity to the secondary factor itself (causal interaction) rather than to some other factor potentially related to it, then confounding variables for the secondary factor must be controlled for.
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Example 2
Sadowski and colleagues' trial of supportive housing for homeless adults with chronic illness (9) provides another example where such concerns may be relevant. Suppose that the effect of supportive housing on the number of hospital days was found to be greater in adults with at least part-time employment. These findings would imply that the effectiveness of treatment could be increased by targeting employed persons. However, the subgroup analysis would not imply that the effect of the housing program itself would increase if persons were given employment along with the supportive housing program.
Employment may be confounded by mental health, such that employment may effectively serve as a proxy for mental health. Supportive housing may be more effective in persons without mental illness. Intervening on employment without changing mental health status may make no difference to the effectiveness of supportive housing. If this were true, a subgroup analysis for employment that controlled for mental health status might eliminate the effect heterogeneity for employment, indicating no causal interaction between employment and the housing program. Control for confounding is not necessary for targeting subgroups, but it is necessary if we are considering interventions on the secondary factor, such as employment in this example.
ADDITIONAL REMARKS
Several further points merit attention. First, our observations are relevant to observational studies as well as to randomized trials. In an observational study, neither the primary exposure nor the secondary factor has been randomized. When effect heterogeneity is of interest in observational studies, only 1 set of confounding factors (for exposure) needs to be controlled for. When interventions on both the exposure and the secondary factor are considered, adjustment needs to be made for both sets of confounding factors. In the context of observational studies, we have discussed elsewhere (10) the distinction and referred to the former setting as one of "effect modification" or "effect heterogeneity" and the latter as "causal interaction."
Second, even when the goal of the subgroup analysis is simply to establish effect heterogeneity, all of the previously mentioned cautionary points about analyzing and reporting subgroup results should be heeded (1) (2) (3) (4) (5) (6) . To ensure the validity of results, prespecified subgroup analyses are preferred over post hoc analyses, issues of multiple testing should be accounted for (5, 6) , formal interaction tests should be performed, and subgroup analyses with some biological plausibility are preferred. These points are relevant regardless of whether effect heterogeneity or potential interventions on the secondary variable are of interest.
Third, although confounding control via multivariate adjustment is not necessary for targeting subpopulations (assessing "effect heterogeneity"), it may still be useful in correcting chance imbalances between treatment and control participants within each subgroup and in generalizing findings and identifying factors that are most relevant.
Fourth, when targeting subgroups to maximize the treatment effect, differences in absolute risk are often most relevant for assessing their importance to public health (4, (11) (12) (13) . Statistical tests to assess effect heterogeneity for absolute risk are described elsewhere (14) . Important differences in absolute risk may exist even in the absence of effect heterogeneity on the relative risk scale, as shown in Figure 2 .
In Figure 2 , the effect of treatment on a ratio scale in subgroup 1 is to increase the percentage of patients whose condition improved 2-fold (from 10% to 20%). Also on the ratio scale, the effect of treatment in subgroup 2 is to increase the percentage of patients whose condition improved 2-fold (from 20% to 40%). There is no effect heterogeneity on the relative risk scale. However, there is effect heterogeneity on the absolute risk scale.
In subgroup 1, treatment increases the percentage of patients whose condition improved by 10 percentage points (from 10% to 20%); in subgroup 2, treatment increases the percentage of patients whose condition improved by 20 percentage points (from 20% to 40%). If resources were limited, subgroup 2 would be the appropriate subgroup to target because a larger proportion of pa- Differences in absolute risk also may give stronger evidence of mechanistic interaction (13, 15) . Investigators who use logistic or proportional hazards models may want to convert estimates to the absolute risk difference scale when performing subgroup analyses. Methods for testing and calculating measures of effect heterogeneity on the absolute risk scale from logistic or proportional hazards models are described elsewhere (16 -18) . These statements comparing absolute risk with relative risk are relevant both for assessing effect heterogeneity and for interventions targeted at changing the secondary factor (causal interaction).
Finally, findings when interventions on the secondary factor are of interest (causal interaction) should be assessed with the same considerations as findings from observational studies, because the secondary factor has not been randomized. It is difficult to know whether adequate adjustment has been made for confounding for a variable that has not been randomized. Subgroup analyses should be interpreted as instances of causal interaction only with caution.
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